Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
presented by
Why Digital Twin Technology Could Help Maximize GLP-1 Efficacy
Digital twin technology can serve as an effective complement to some of the exciting advancements occurring in the metabolic health space, such as new generations of continuous glucose monitors and a slew of GLP-1s, according to Lisa Shah, chief medical officer at Twin Health.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study
The weight loss results for the Terns Pharmaceuticals drug TERN-601 come from a four-week Phase 1 clinical trial. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class.
New Data Network Seeks to Provide Much-Needed Info on GLP-1s
OMNY Health — a national data ecosystem that facilitates biotech and medical research — launched a data network consisting of EHR data from more than 645,000 GLP-1 users. The data network seeks to give OMNY’s life sciences and health system partners a vast source of GLP-1 data that is related to patient demographics and social determinants of health.
Roche Weighs In With Encouraging Early Clinical Data for Oral GLP-1 Drug
Roche reported its oral GLP-1 agonist led to an average 6.1% weight loss at four weeks, according to preliminary results from part of a Phase 1 study. The small molecule comes from Roche’s $2.7 billion acquisition of Carmot Therapeutics last year.
Hims & Hers Offers Access to GLP-1s Starting At $199 A Month
Hims & Hers is now providing access to compounded GLP-1s. Patients also receive unlimited medical consultations with a licensed provider.
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
‘The Time Is Now’: How Employers Can Offer Comprehensive Obesity Care
Employers are in a unique position to drive change in obesity care, but face several challenges. Experts shared numerous strategies employers can implement.
Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds
Amgen is confident its injectable obesity drug would have a differentiated profile compared to medications now on the market from Novo Nordisk and Eli Lilly and it’s now preparing for Phase 3 testing. But an oral obesity drug in Amgen’s pipeline will not advance beyond Phase 1.
MedCity FemFwd: Inside the EveryBODY Covered Campaign Aiming To Improve Obesity Care Coverage
In this episode, we’re joined by Millicent Gorham, CEO of the Alliance for Women’s Health and Prevention (AWHP). AWHP recently launched the EveryBODY Covered campaign, which is advocating for comprehensive coverage of obesity care. Gorham discusses the current state of obesity treatment for women and her goals for the campaign.
Omada Expands GLP-1 Care Track To Include Exercise Plans, Member Level Reporting
Omada's newly expanded GLP-1 Care Track provides tailored exercise plans, support for getting off of GLP-1s and calorie tracking. It also offers insight into who is responding to GLP-1s and who is engaging in Omada's program.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
We’ve Actually Treated Tens of Thousands of People on Ozempic to Date – Here’s What Really Happens and What It Likely Means for Solving Our Obesity Epidemic
We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.
How Are Payers Approaching Obesity Management?
GLP-1s continue to be in high demand, and the healthcare industry is watching closely to see how payers decide to cover the drugs going forward. During a virtual panel, payer executives noted that it's important to remember that GLP-1s won’t be able to solve the country’s obesity crisis by themselves.
Disruption from Weight Loss Drugs Has Only Scratched the Surface. Telehealth Can Help Overcome the Next Big Obstacle
Telehealth is poised to serve as an essential tool to fill an exploding demand for care. Providers and digital health companies need to act now by expanding telehealth offerings that include on-demand care teams knowledgeable and experienced in GLP-1 drugs, but also overall health and wellness strategies.
The Prohibitive Economics of Weight Care
How we discuss overweight and obese diagnoses and how we treat those patients is slowly starting to improve. However, there’s still a lot of work to be done – in how we manufacture, market, and manage life-changing weight care medications, as well as how we expand access and improve adherence to them.
FDA’s Preliminary Review of GLP-1 Meds Finds No Tie to Suicidal Thoughts, Actions
The FDA has found no clear relationship between GLP-1 drugs, such as Ozempic and Mounjaro, and reports of suicidal thoughts or actions. But the agency added that it can’t definitively rule out the risk, and its review is ongoing.